Like I said, PD1-Vaxx is the 4th most important IP so if a sponsor want to advance this IP to Ph2 then IMU has let them. The clinical trial update "soon" for OASIS will be crucial otherwise it's all up to Azer-Cel and they have enough fund until registrational clinical trial but the rerate will likely be to 5c, I can't see the pps rerate to 10c without positive clinical trial update for OASIS or additional CR from the CCA expansion for VAXINIA 6 months later with the data used from the poster presentation.
IMU Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)